LY 3023703

Drug Profile

LY 3023703

Alternative Names: [^14C]-LY3023703; LY-3023703

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Analgesics; Antirheumatics
  • Mechanism of Action Prostaglandin-E synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute pain; Dental pain; Musculoskeletal pain

Most Recent Events

  • 29 Jan 2014 Eli Lilly terminates phase I trial in Healthy volunteers in the USA (NCT01965782)
  • 23 Jan 2014 Discontinued - Phase-I for Acute pain (in volunteers) in USA (PO)
  • 23 Jan 2014 Discontinued - Phase-II for Dental pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top